GYRE - GYRE THERAPEUTICS, INC.
9.53
0.050 0.525%
Share volume: 151,613
Last Updated: 05-09-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.09%
PREVIOUS CLOSE
CHG
CHG%
$9.48
0.05
0.01%
Summary score
49%
Profitability
53%
Dept financing
32%
Liquidity
75%
Performance
43%
Sector
Manufacturing
Industry
Pharmaceutical Products/Pharmaceutical Preparations
Long-term ratios 2021 - 2025
The data are presented for the financials results of the quarters of the last 4 years.
Return on equity
-67.4%
Return on assets
-12%
Return on sales
-544.32%
Return on invested capital
-106.2%
Total debt ratio
41.32%
Debt ratio change over timeo
-1.49%
Current Ratio
5.23%
Quick Ratio
5.1%
Cash Position Ratio
3.73%
Short-term ratios 2024 - 2025
The data are presented for the financials results of the quarters of the last year.
Return on equity
0%
Return on assets
2.83%
Return on sales
10.5%
Return on invested capital
0%
Total debt ratio
49.17%
Debt ratio change over timeo
0%
Current Ratio
3.52%
Quick Ratio
3.14%
Cash Position Ratio
0.88%
Last quarter ratios 2025
The data are presented for the financials results of the last quarter.
Return on equity
0%
Return on assets
3.57%
Return on sales
10.3%
Return on invested capital
0%
Total debt ratio
47.51%
Debt ratio change over time
0%
Current Ratio
3.6%
Quick Ratio
3.19%
Cash Position Ratio
0.79%
Performance ratios (change over 4 years) 2021 - 2025
The data are presented for the change financials results of the quarter of the last 4 years.
Return on equity
-37.35%
Return on assets
-95.33%
Return on sales
-580.9%
Return on invested capital
-66.82%
Total debt ratio
-148.64%
Debt ratio change over time
-1.49%
Current Ratio
-1.82%
Quick Ratio
-1.78%
Cash Position Ratio
-1.46%
Compare in sector
The following table compares the individual analyzes for the other top 3 stocks within the same industry.
| Long-term ratios | GYRE | LLY | JNJ | NVO |
|---|---|---|---|---|
| Return on equity | -67.4% | 14.28% | 9.23% | 0% |
| Return on assets | -12% | 4.23% | 3.2% | 0% |
| Return on sales | -544.32% | 27.89% | 25.03% | 0% |
| Return on invested capital | -106.2% | 8.36% | 9.37% | 0% |
| Profitability | 0% | 97% | 83% | 0% |
| Total debt ratio | 41.32% | 81.28% | 59.58% | 0% |
| Debt ratio change over time | -1.49% | -11.36% | -57.43% | 0% |
| Dept financing | 13% | 25% | 18% | 25% |
| Current Ratio | 3.52% | 1.23% | 1.12% | 0% |
| Quick Ratio | 3.14% | 0.95% | 0.88% | 0% |
| Cash Position Ratio | 0.88% | 0.12% | 0.5% | 0% |
| Liquididy | 75% | 11% | 14% | 0% |
| Short-term ratios | GYRE | LLY | JNJ | NVO |
|---|---|---|---|---|
| Return on equity | 0% | 0% | 0% | 0% |
| Return on assets | 2.83% | 4.32% | 3.49% | 0% |
| Return on sales | 10.5% | 28.32% | 23.63% | 0% |
| Return on invested capital | 0% | 0% | 0% | 0% |
| Profitability | 76% | 50% | 41% | 0% |
| Total debt ratio | 49.17% | 81.66% | 60.28% | 0% |
| Debt ratio change over time | 0% | 0% | 0% | 0% |
| Dept financing | 40% | 25% | 18% | 0% |
| Current Ratio | 3.52% | 1.23% | 1.12% | 0% |
| Quick Ratio | 3.14% | 0.95% | 0.88% | 0% |
| Cash Position Ratio | 0.88% | 0.12% | 0.5% | 0% |
| Liquididy | 75% | 20% | 29% | 0% |
